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Summary
Five days following the 3rd cycle of nivolumab, a monoclonal antibody, which acts as immune checkpoint inhibitor 
against the programmed cell death protein-1, for metastatic lung adenocarcinoma, a 56-year-old woman presented 
at the hospital critically ill. On admission, she had severe diabetic ketoacidosis (DKA), as evidenced by venous glucose 
of 47 mmol/L, blood ketones of 7.5 mmol/L, pH of 6.95 and bicarbonate of 6.6 mmol/L. She has had no personal or 
family history of diabetes mellitus (DM), while random venous glucose, measured 1 week prior to hospitalisation, 
was 6.1 mmol/L. On admission, her HbA1c was 8.2% and anti-GAD antibodies were 12 kIU/L (0–5 kU/L), while islet cell 
antibodies and serum C-peptide were undetectable. Nivolumab was recommenced without the development of other 
immune-mediated phenomena until 6 months later, when she developed hypothyroidism with TSH 18 U/L and low free T4. 
She remains insulin dependent and has required levothyroxine replacement, while she has maintained good radiological 
and clinical response to immunotherapy. This case is notable for the rapidity of onset and profound nature of DKA at 
presentation, which occurred two months following commencement of immunotherapy. Despite the association of 
nivolumab with immune-mediated endocrinopathies, only a very small number of patients developing type 1 DM has 
been reported to date. Patients should be closely monitored for hyperglycaemia and thyroid dysfunction prior to and 
periodically during immunotherapy.
Background
The programmed cell death-1 protein (PD-1) is an 
immune checkpoint, a cell surface protein found on 
activated T cells, which, through interaction with its 
ligands, PD-L1 and PD-L2, inhibits kinase signalling 
pathways that normally lead to T-cell activation (1). 
Several tumour types can evade host immune surveillance 
by downregulating cytotoxic T-cell signalling through 
the upregulation of PD-L1 expression (2). This pathway 
is targeted by anti-PD-1 agents (3). Nivolumab is an 
anti-PD-1 monoclonal antibody that selectively blocks 
the interaction of the cancer cell PD-L1 and the PD-1 
receptor of the activated T cells; as a result, T cells, instead 
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Learning points:
 • Nivolumab can induce fulminant type 1 diabetes, resulting in DKA.
 • Nivolumab is frequently associated with thyroid dysfunction, mostly hypothyroidism.
 • Nivolumab-treated patients should be monitored regularly for hyperglycaemia and thyroid dysfunction.
 • Clinicians should be aware and warn patients of potential signs and symptoms of severe hyperglycaemia.
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of undergoing apoptosis, are capable of surviving and 
help to eliminate cancer cells (3). Therefore, nivolumab 
acts as an immunomodulatory antibody that ultimately 
augments the anticancer immune response through 
downregulation of T-cell inhibition.
Nivolumab was introduced and firstly approved for 
the treatment of melanoma, but has an increasing role in 
other tumours such as non-small-cell lung cancer (NSCLC) 
(4), renal cell carcinoma, head and neck squamous cell 
carcinoma (HNSCC), Hodgkin’s lymphoma and urothelial 
carcinoma. An improvement in the overall survival in a 
multicentre, randomised, open-label trial comparing 
nivolumab to docetaxel formed the basis for approval by 
the regulatory authorities in 2015 for the use of this drug 
in previously treated metastatic NSCLC (4).
As immune checkpoint inhibitors enhance T-cell 
immunity by disrupting the inhibitory signalling for the 
purpose of an increased anti-tumour response, they also 
reduce immune tolerance and, thereby cause autoimmune 
toxicities. These immune-related adverse events affect 
dermatological, gastrointestinal, hepatic, endocrine 
and other systems, with the commonest adverse effects 
being immune-related hepatitis, colitis and pneumonitis. 
Several immune-mediated endocrinopathies, such as 
autoimmune thyroid disorders, hypophysitis and adrenal 
insufficiency, are well recognised. However, only very few 
cases of type 1 diabetes mellitus (DM) have been reported 
so far.
The case presented here is notable because of the 
rapidity of development of type 1 DM in combination 
with the severity of diabetic ketoacidosis (DKA). In 
addition, this is the second case ever reported in the 
literature of autoimmune diabetes and hypothyroidism 
complicating nivolumab therapy.
Case presentation
Five days following the 3rd cycle of nivolumab as second-
line treatment for metastatic lung adenocarcinoma, a 
56-year-old Caucasian woman presented at the hospital 
critically ill. She was initially diagnosed with non-
small-cell lung cancer three years ago and treated with 
pemetrexed and cisplatin. Subsequently, she received 
pemetrexed as maintenance chemotherapy until it was 
discontinued due to side effects two months prior to 
her emergency presentation. At that stage, therapy with 
nivolumab every 2 weeks was initiated with the patient 
showing good radiological and clinical response to it.
On admission, she was disorientated, agitated 
and combative without evidence of haemodynamic 
compromise and required sedation and intubation to 
permit assessment and initial resuscitation. She had 
severe metabolic acidosis predominantly due to diabetic 
ketoacidosis (DKA), as evidenced by glucose of 47 mmol/L 
(846 mg/dL), blood ketones of 7.5 mmol/L, pH of 6.95 and 
bicarbonate of 6.6 mmol/L.
In retrospect, she reported severe polyuria and 
polydipsia for the preceding 48 h, while one week prior to 
presentation, she was clinically well and normoglycaemic 
with random venous glucose of 6.1 mmol/L (110 mg/dL). 
Apart from metastatic lung adenocarcinoma, she had no 
personal/family history of DM or other organ-specific 
autoimmune conditions. Venous glucose had been normal 
at numerous measurements, while there was no evidence 
of pancreatic involvement, as evidenced by unremarkable 
appearances in CT abdomen, which was performed 2 days 
prior to emergency presentation.
Investigation
The patient had evidence of acute kidney injury with 
serum creatinine elevated at 300 µmol/L, compared 
to a baseline of 120 µmol/L. Her HbA1c on admission 
was 8.2%, as seen in Table  1. She was biochemically 
euthyroid and had appropriately elevated serum cortisol 
>1000 nmol/L. Her adrenal, thyroid peroxidase and 
islet cell antibodies were undetectable, while anti-GAD 
antibodies were present at 12 kU/L (0–5 kU/L). Serum 
C-peptide was also inappropriately undetectable. She has 
not been HLA genotyped.
Biochemical values, prior to, at the time of 
presentation, and after, are illustrated in Table 1.
Treatment
She responded well to standard treatment for DKA. In 
specific, she required infusion of large volumes (11 L) 
of isotonic saline over the first 48 h and continuous 
intravenous insulin infusion with daily requirements of 
72 units in the first 24 h and 59 units in the subsequent 
24 h. She was extubated 24 h following admission, and 
her cognitive state normalised. However, at the initial 
stages of recovery, she was susceptible to unpredictable 
ketosis. Shortly after conversion to subcutaneous insulin 
administration on day 3 of hospitalisation, she rapidly 
developed hyperglycaemia and ketosis with blood glucose 
of about 20 mmol/L and ketones of 2.0 mmol/L, requiring 
reinstatement of intravenous insulin infusion for a few 
hours. In the following 2  days, blood glucose readings 
ranged between 2.5 and 21.5 mmol/L. Another episode 
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of short-lived hyperglycaemic ketosis occurred 24 h later, 
which rapidly resolved with subcutaneous administration 
of an additional dose of rapid-acting insulin.
Outcome and follow-up
After developing fulminant type 1 DM leading to severe 
DKA, this patient remains insulin dependent. She 
exhibits significant glycaemic variability and her insulin 
requirements have gradually increased. One year after 
her diagnosis with nivolumab-induced type 1 DM, she is 
treated with basal bolus insulin regimen in the form of 
24 units of insulin glargine and 1 unit of insulin aspart 
per 10 g of carbohydrate with an overall 24-h insulin 
requirement of approximately 54 units. Her most recent 
HbA1c was 9.1% (76 mmol/L).
Her oncologist recommenced nivolumab therapy 
1  month after development of DM, and she has 
maintained good radiological and clinical response to 
immunotherapy.
No other immune-mediated phenomena were 
reported until 6 months following her presentation with 
DKA when she developed subclinical hypothyroidism 
with TSH: 11.1 U/L and normal fT4 of 12.6 pmol/L 
(normal range: 12–22 pmol/L). Three weeks later, thyroid 
dysfunction progressed with TSH rising to 18.9 U/L and 
fT4 below the lower end of normal range at 11.2 pmol/L. 
She also developed symptoms, such as fatigue, cold 
intolerance and weight gain of 3 kg, necessitating initiation 
of levothyroxine replacement at a dose of 50 µg/day. Since 
then, she remains clinically and biochemically euthyroid 
on the current 50 µg daily dose of levothyroxine.
With respect to the possibility of other autoimmune 
endocrinopathies, she undergoes periodical testing, 
which has not shown deficiency of any other anterior 
pituitary hormones. In specific, most recent serum 09:00 h 
cortisol was 420 mmol/L, IGF-1: 14.4 (normal range: 
5.6–22.9 nmol/L) and prolactin 226 U/L (normal range: 
102–496 U/L), while FSH and LH remain appropriately 
elevated at 101.9 IU/L and 62.9 IU/L in keeping with her 
postmenopausal status.
Discussion
A few case reports have been published of rapid onset 
type 1 DM after initiation with anti-PD-1 monoclonal 
antibody treatment. The largest case series of five patients 
with an onset of diabetes occurring between 1 and 
5  months following the commencement of anti-PD-1 
drugs (5) cannot attribute DM to immunotherapy with 
certainty because of the presence of other risk factors 
like co-administration of other immunomodulators, the 
presence of pancreatic metastases and pre-existing type 2 
diabetes. The first Asian patient to develop type 1 diabetes 
with nivolumab therapy was described by Okamoto et al. 
(6). Our case report as well as other reported cases are 
characterised by the rapid onset of insulin-dependent 
DM in close proximity with the initiation of nivolumab. 
Further cases (7) have been reported primarily in patients 
in Japan, where fulminant type 1 DM is recognised to 
occur spontaneously within the population, though these 
patients had been receiving nivolumab for between 4 and 
12 months.
Table 1 Blood biochemical parameters one month and one week prior to, at the time of presentation and one week after 
discharge.
1 month before 1 week before At the time of presentation 1 week after
Glucose (mmol/L) 5.1 6.1 47.0 14.2
Sodium (mmol/L) 136 141 131 140
Potassium (mmol/L) 4.4 4.4 5.3 4.4
Urea (mmol/L) 22.4 4.8
Creatinine (µmol/L) 122 119 300 128
Haemoglobin (g/L) 134 131 137 118
WCC (×109/L) 6.1 5.7 19.1 7.9
CRP (mg/L) 1 1 28 5
HbA1c 8.2 (66)
pH 6.95
pCO2 (kPa) 3.2
pO2 (kPa) 18.4
Bicarbonate (mmol/L) 6.6
Lactate (mmol/L) 2.3
Chloride (mmol/L) 105
Ketones (mmol/L) 7.5
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As many MHC-linked and non-MHC-linked genes 
and genetic regions in humans and mice, determining 
the susceptibility to autoimmune diseases, have 
been identified, further work in mice suggests that 
immunotherapy may precipitate diabetes development in 
those with these susceptible HLA alleles (8). In humans, 
there is a preponderance of high risk HLA alleles in 
individuals who have developed type 1 DM in the 
context of PD-1 immunotherapy (9), supporting a genetic 
predisposition to this complication of therapy. The 
biological plausibility of these drugs inducing diabetes 
is supported by experimental work where inhibition of 
the PD-1/PD-L1 interaction rapidly precipitated diabetes 
in prediabetic non-obese diabetic (NOD) mice, especially 
in older mice (10). Thus, PD-1 appears to be critical for 
progression of autoimmune diabetes in susceptible 
individuals (10).
PD-1 inhibitors, nivolumab and pembrolizumab, 
have been associated with a high incidence of thyroid 
dysfunction (11, 12, 13). Phase 3 studies of nivolumab 
therapy for malignant melanoma and non-squamous 
non-small cell lung cancer (4) have reported a frequency 
for hypothyroidism of 5.6–6.6% and for thyrotoxicosis 
of 1.4–1.9% respectively. Noteworthy, the risk of thyroid 
abnormalities increases substantially when patients 
are treated with a combination of PD-1 and CTLA-4 
(cytotoxic T-lymphocyte antigen-4) inhibitors (14, 15) 
or when PD-1 inhibitor follows CTLA-4 therapy, such 
as ipilimumab, especially when the wash-out period 
is <4  weeks (15). The most commonly described types 
of nivolumab-related thyroid dysfunction are either 
a transient thyrotoxic phase, which tends to resolve 
spontaneously and is often followed by hypothyroidism 
(11) or development of isolated hypothyroidism, both 
caused by painless thyroiditis (12). Thyrotoxicosis tends 
to occur within 6 weeks after the first administration of 
nivolumab. However, the time to onset of hypothyroidism 
ranges from 4  days to months following initiation of 
immunotherapy, making it very difficult to predict the 
occurrence time (11, 12, 14, 15). Finally, it has been 
suggested that new occurrence of thyroid and extra-
thyroid autoimmune disorders may be associated with a 
better treatment response to PD-1 inhibitors (13, 15), but 
this finding needs to be studied further.
A high incidence of positive thyroid peroxidase 
antibodies (anti-TPO antibodies) and thyroglobulin 
antibodies (anti-TG antibodies) has been reported in 
patients with nivolumab-induced thyroid dysfunction 
(11, 12, 13, 16), while Maekura and coworkers recently 
suggested that positive anti-TPO and anti-TG antibodies at 
baseline may predict nivolumab-induced hypothyroidism 
(16). These data provide evidence for a possible link of 
immunologic pathways with nivolumab-induced thyroid 
dysfunction. It is also known that PD-L1 and PD-L2 
are expressed in normal thyroid tissue. Consequently, 
inhibiting the PD-1 pathway could be correlated 
with reduced immune tolerance and development of 
thyroiditis (12). In addition, polymorphic variants of the 
PD-1 receptor gene may be related to the occurrence of 
painless thyroiditis (11).
The rapidity of onset and profound nature of the 
diabetic ketoacidosis at presentation in our non-Asian 
patient, which occurred two months following the 
commencement of immunotherapy and was followed 
by the development of hypothyroidism 6 months later, 
highlight the need for regular patient monitoring in order 
to promptly identify immune-related endocrinopathies. 
In addition, clinicians should be aware and warn 
patients of potential signs and symptoms indicative of 
hyperglycaemia. In our practice, we monitor glucose levels 
every 2  weeks during the period of nivolumab therapy. 
We also educate patients on symptoms of hyperglycaemia 
and provide them with blood glucose monitor to check 
glucose levels in case of hyperglycaemic symptoms. 
Serum concentration of TSH and free T4 is measured prior 
to and 2-weekly after nivolumab therapy. Moreover, all 
patients who have already developed a nivolumab-related 
endocrine adverse event undergo periodical monitoring 
for other possible endocrinopathies. For example, in our 
case, we regularly measure early morning serum cortisol 
in view of the risk for hypophysitis or adrenalitis.
Despite a recent systematic review and meta-analysis 
of 7551 patients in 38 randomised trials reporting an 
overall incidence of about 10% for immunotherapy-
related clinically significant endocrinopathies (17), 
immunotherapy is usually not discontinued since its 
favourable outcomes seem to outweigh these adverse 
events (3). Studies are warranted to identify the risk 
factors for development of immunotherapy-induced type 
1 diabetes (3), but also the frequency and natural history 
of this adverse event. The same need for prospective 
studies applies to examining the utility of baseline 
evaluation of thyroid TPO or/and TG antibodies as a 
predictor for development of thyroid dysfunction (16). 
Most importantly, patients and healthcare professionals 
should be well educated on symptom recognition 
and management of these endocrinopathies while on 
immunotherapy.
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